Lu-Te Chang - 臺北醫學大學

查看斯高帕斯 (Scopus) 概要

電子郵件19571s.tmu.edutw

h-index

每年研究成果

學歷

國立陽明大學醫學系學士

指紋

查看啟用 Lu-Te Chang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。

1 類似的個人檔案

2 回顧型文獻
1 文章
1 快報

Fertility preservation for women with breast cancer before chemotherapy: a systematic review and meta-analysis
Chen, C. N., Chang, L. T., Chen, C. H. & Tam, K. W., 2月 2022, 於: Reproductive BioMedicine Online. 44, 2, p. 357-369 13 p.
研究成果: 雜誌貢獻 › 回顧型文獻 › 同行評審

開啟存取
13 引文斯高帕斯（Scopus）
Author's Reply
Tsai, M. C., Chang, L. T. & Tam, K. W., 11月 2021, 於: Journal of Minimally Invasive Gynecology. 28, 11, p. 1955-1956 2 p.
研究成果: 雜誌貢獻 › 快報 › 同行評審
Comparison of High-Intensity Focused Ultrasound and Conventional Surgery for Patients with Uterine Myomas: A Systematic Review and Meta-Analysis
Tsai, M. C., Chang, L. T. & Tam, K. W., 10月 2021, 於: Journal of Minimally Invasive Gynecology. 28, 10, p. 1712-1724 13 p.
研究成果: 雜誌貢獻 › 回顧型文獻 › 同行評審
20 引文斯高帕斯（Scopus）
Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
Lin, Y. C., Wen, K. C., Sung, P. L., Chou, Y. T., Liew, P. L., Chen, L. Y., Huang, R. L., Lai, H. C. & Chang, L. T., 12月 2020, 於: Journal of Ovarian Research. 13, 1, 143.
研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取
8 引文斯高帕斯（Scopus）

Additional file 1 of Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
Lin, Y.-C. (Contributor), Wen, K.-C. (Creator), Sung, P.-L. (Contributor), Chou, Y.-T. (Creator), Liew, P.-L. (Contributor), Chen, L.-Y. (Contributor), Huang, R.-L. (Creator), Lai, H.-C. (Contributor) & Chang, L.-T. (Contributor), Figshare, 2020
DOI: 10.6084/m9.figshare.13352142.v1, https://springernature.figshare.com/articles/figure/Additional_file_1_of_Complete_remission_of_heavily_treated_ovarian_clear_cell_carcinoma_with_ARID1A_mutations_after_pembrolizumab_and_bevacizumab_combination_therapy_a_case_report/13352142/1
資料集: Dataset
Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
Lin, Y.-C. (Contributor), Wen, K.-C. (Creator), Sung, P.-L. (Contributor), Chou, Y.-T. (Creator), Liew, P.-L. (Contributor), Chen, L.-Y. (Contributor), Huang, R.-L. (Creator), Lai, H.-C. (Contributor) & Chang, L.-T. (Contributor), Figshare, 2020
DOI: 10.6084/m9.figshare.c.5234313.v1, https://springernature.figshare.com/collections/Complete_remission_of_heavily_treated_ovarian_clear_cell_carcinoma_with_ARID1A_mutations_after_pembrolizumab_and_bevacizumab_combination_therapy_a_case_report/5234313/1
資料集: Dataset